Surmodics Q2 EPS Forecast Lowered by Barrington Research

Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Barrington Research cut their Q2 2026 EPS estimates for Surmodics in a research report issued on Thursday, May 1st. Barrington Research analyst M. Petusky now anticipates that the company will post earnings of $0.01 per share for the quarter, down from their prior estimate of $0.03. The consensus estimate for Surmodics' current full-year earnings is $0.20 per share. Barrington Research also issued estimates for Surmodics' Q3 2026 earnings at $0.01 EPS, Q4 2026 earnings at $0.07 EPS and FY2027 earnings at $0.28 EPS.

A number of other analysts have also commented on SRDX. StockNews.com started coverage on Surmodics in a report on Monday, February 3rd. They set a "hold" rating for the company. Lake Street Capital raised Surmodics from a "hold" rating to a "buy" rating and set a $43.00 target price on the stock in a research note on Friday, March 7th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Surmodics in a report on Wednesday, April 30th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $43.00.

Surmodics Price Performance

Shares of SRDX traded down $0.67 during trading hours on Friday, reaching $26.97. The stock had a trading volume of 83,317 shares, compared to its average volume of 277,437. The company's 50-day moving average is $29.43 and its two-hundred day moving average is $34.86. Surmodics has a 12 month low of $26.00 and a 12 month high of $42.44. The stock has a market capitalization of $385.64 million, a PE ratio of -26.70 and a beta of 1.32. The company has a debt-to-equity ratio of 0.26, a quick ratio of 4.29 and a current ratio of 5.45.

Surmodics (NASDAQ:SRDX - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.07). The company had revenue of $28.09 million during the quarter, compared to analyst estimates of $32.23 million. Surmodics had a negative net margin of 11.48% and a negative return on equity of 4.39%.

Institutional Trading of Surmodics

Several hedge funds have recently modified their holdings of the company. Barclays PLC grew its position in Surmodics by 16.0% during the 3rd quarter. Barclays PLC now owns 88,750 shares of the company's stock worth $3,443,000 after purchasing an additional 12,271 shares during the period. Principal Financial Group Inc. purchased a new position in shares of Surmodics in the third quarter worth about $1,190,000. JPMorgan Chase & Co. increased its holdings in shares of Surmodics by 192.7% in the third quarter. JPMorgan Chase & Co. now owns 42,470 shares of the company's stock valued at $1,647,000 after purchasing an additional 27,960 shares during the last quarter. Modus Advisors LLC acquired a new position in shares of Surmodics during the 4th quarter valued at about $40,000. Finally, SG Americas Securities LLC increased its holdings in shares of Surmodics by 22.1% during the 4th quarter. SG Americas Securities LLC now owns 6,940 shares of the company's stock worth $275,000 after buying an additional 1,255 shares during the last quarter. 96.63% of the stock is owned by hedge funds and other institutional investors.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).